<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Darryl Quarles, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jessica Kendrick, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic reviews refractory hyperparathyroidism and the indications for parathyroidectomy among patients on chronic dialysis. The medical management of hyperparathyroidism is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p>Surgical approaches to parathyroidectomy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15041.html" rel="external">"Parathyroidectomy in end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H1191655663"><span class="h1">DEFINITIONS AND PATHOGENESIS</span><span class="headingEndMark"> — </span>We define refractory hyperparathyroidism as severe, persistent, and progressive elevation of serum parathyroid hormone (PTH) that cannot be treated adequately by medical therapy (including both vitamin D analogs and calcimimetics) without causing significant hyperphosphatemia or hypercalcemia.</p><p>There is no consensus on a PTH level that defines refractory hyperparathyroidism. Some clinicians define refractory hyperparathyroidism as a PTH level persistently &gt;800 pg/mL, which is the level at which parathyroidectomy is often considered in symptomatic patients. Other clinicians use the Kidney Disease: Improving Global Outcomes (KDIGO) PTH target threshold for treatment, which is nine times above the upper limit of normal for the PTH assay (ie, 585 pg/mL if upper range of normal is 65 pg/mL). However, a parathyroidectomy is generally not performed at this level of PTH. (See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p>Severe hyperparathyroidism that is refractory to medical therapy suggests tertiary hyperparathyroidism, in which there is autonomous secretion of PTH that is not responsive to the plasma calcium concentration [<a href="#rid1">1</a>]. Tertiary hyperparathyroidism is often associated with hypercalcemia (in the absence of medications such as <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>, vitamin D, or calcium-containing phosphate binders) and symptoms and signs of high bone turnover. (See <a class="local">'Signs and symptoms'</a> below.)</p><p>Tertiary hyperparathyroidism develops after prolonged parathyroid stimulation from hypocalcemia, <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> deficiency, and hyperphosphatemia. These stimuli increase PTH synthesis and parathyroid cell proliferation [<a href="#rid2">2-5</a>]. Somatic mutations in the proliferating parathyroid cells lead to monoclonal expansion or adenomatous transformation of the tissue that can manifest as nodular hyperplasia and enlargement of the parathyroid glands [<a href="#rid6">6</a>]. Such transformed parathyroid cells do not respond to the normal PTH-suppressive stimuli, such as normalization of the serum calcium concentration or treatment with calcitriol. This lack of response to PTH-suppressive stimuli may be caused by reduced expression of the extracellular calcium-sensing receptor [<a href="#rid2">2</a>], lower-density of the vitamin D receptor [<a href="#rid3">3</a>], and decreased expression of klotho and fibroblast growth factor receptor 1 [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1149862450"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of refractory hyperparathyroidism is difficult to estimate because of variability in the definition and evolution in the medical therapies used to treat hyperparathyroidism. Because it is a definitive treatment for refractory hyperparathyroidism, the rate of parathyroidectomy is used to provide an estimate of prevalence.</p><p>Among patients on dialysis, the rate of parathyroidectomy for refractory hyperparathyroidism is approximately 7 to 10 per 1000 patient-years [<a href="#rid8">8,9</a>]. This rate has remained largely constant over the past several years despite advances in medical therapy, including the development of calcimimetic agents, such as <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a>, which decrease the risk for hypercalcemia [<a href="#rid10">10</a>].</p><p><a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">Cinacalcet</a> reduces the risk of parathyroidectomy [<a href="#rid11">11,12</a>]. This was demonstrated in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) randomized trial, in which patients were assigned to receive cinacalcet or placebo in addition to conventional therapy including phosphate binders and/or active vitamin D or synthetic analogs [<a href="#rid11">11</a>]. The rate of parathyroidectomy was lower in cinacalcet-treated patients compared with placebo (relative hazard ratio [HR] 0.44, 95% CI 0.36-0.54) [<a href="#rid10">10,11</a>].</p><p>However, an analysis of data from a national database spanning 2002 to 2011 showed that, although the rate of parathyroidectomies decreased between 2004 and 2005 (coinciding with availability of <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> in the United States), the rate rose again in 2006 and remained stable thereafter, despite more widespread cinacalcet use [<a href="#rid10">10</a>]. A suggested reason for the discrepancy is that doses used in EVOLVE were higher than those used in clinical practice [<a href="#rid10">10</a>].</p><p>It is unclear whether the introduction of newer calcimimetic agents may reduce rates of parathyroidectomy among patients on dialysis. In patients on dialysis, the intravenous calcimimetic <a class="drug drug_general" data-topicid="111821" href="/z/d/drug information/111821.html" rel="external">etelcalcetide</a> lowers PTH levels more than <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> [<a href="#rid13">13,14</a>] and is effective in many cases of severe hyperparathyroidism [<a href="#rid15">15</a>]. </p><p>Refractory hyperparathyroidism requiring parathyroidectomy is far less common among chronic kidney disease (CKD) patients who are not on dialysis. In an analysis of 32,971 admissions for parathyroidectomy for secondary hyperparathyroidism performed in the United States between 2002 and 2011, 76 percent were performed in patient who had diagnostic or procedure codes specific for dialysis, whereas the remainder had other codes for kidney failure or transplantation [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H1627812280"><span class="h1">SIGNS AND SYMPTOMS</span><span class="headingEndMark"> — </span>The most common signs and symptoms of refractory hyperparathyroidism include [<a href="#rid16">16,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bone and joint pain </p><p class="bulletIndent1"><span class="glyph">●</span>Fractures</p><p class="bulletIndent1"><span class="glyph">●</span>Proximal muscle weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Extraskeletal calcification (eg, in the vasculature)</p><p class="bulletIndent1"><span class="glyph">●</span>Calciphylaxis</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperphosphatemia</p><p></p><p>Bone and joint pain can be from osteitis fibrosa cystica, which is a high-turnover form of renal osteodystrophy resulting from unremitting hyperparathyroidism [<a href="#rid17">17</a>]. Pain is primarily present in weight-bearing joints, such as hips, knees, ankles, and lower back, and is generally relieved by rest [<a href="#rid16">16</a>]. Periarticular calcium deposits may cause acute joint inflammation and manifest with pain and stiffness [<a href="#rid17">17</a>]. Some patients present with nontraumatic or nonhealing fractures [<a href="#rid16">16</a>]. Spontaneous tendon ruptures, primarily involving the quadriceps, Achilles, and patellar tendons can occur, although these are uncommon [<a href="#rid18">18-21</a>]. </p><p>Extraskeletal calcification may occur in vasculature and may be visible on imaging or present as calciphylaxis. (See  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a> and  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a>.)</p><p>Brown tumors, which are fibrotic, cystic, lytic bone lesions, can also occur in severe refractory hyperparathyroidism. A rare disfiguring manifestation of severe hyperparathyroidism is Leontiasis ossea or lion face syndrome [<a href="#rid22">22</a>]. </p><p>Most clinical manifestations of hyperparathyroidism generally occur at a parathyroid hormone (PTH) level of over 1000 pg/mL. In the studies reporting on tendon rupture, patients had PTH levels of 1400 to 2000 pg/mL [<a href="#rid20">20,21</a>]. However, certain manifestations are often difficult to ascribe solely to hyperparathyroidism due to their nonspecific nature and overlap with other symptoms common among patients on dialysis. As examples: hyperphosphatemia is ubiquitous and difficult to control among patients on dialysis regardless of refractory hyperparathyroidism; hypercalcemia may occur from use of vitamin D analogs or calcium-containing phosphate binders; and bone pain is common with other types of renal osteodystrophy, including those not associated with hyperparathyroidism.</p><p class="headingAnchor" id="H3"><span class="h1">POTENTIAL INDICATIONS FOR PARATHYROIDECTOMY</span><span class="headingEndMark"> — </span>Most experts agree that patients who have refractory hyperparathyroidism and significant associated signs and symptoms should be referred for parathyroidectomy. A much more controversial issue is whether patients with refractory hyperparathyroidism, but limited or no associated signs or symptoms, should also undergo parathyroidectomy. Among such patients, there is no consensus regarding indications for parathyroidectomy.</p><p class="headingAnchor" id="H4"><span class="h2">Symptomatic patients</span><span class="headingEndMark"> — </span>We generally refer for a parathyroidectomy patients who have severe hyperparathyroidism despite optimal medical management that is accompanied by hyperparathyroid-related signs and symptoms. Parathyroidectomy is effective in treating the signs and symptoms of severe hyperparathyroidism [<a href="#rid23">23-27</a>].</p><p>Optimal medical management is defined as treatment with phosphate binders, active vitamin D analogs, and calcimimetics. (See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Treatment approach'</a>.)</p><p>As noted above, the threshold parathyroid hormone (PTH) value that provides an indication for parathyroidectomy among patients with signs or symptoms is not known. We believe that, for most patients, parathyroidectomy should <strong>not</strong> be performed unless PTH levels are consistently &gt;800 pg/mL [<a href="#rid28">28</a>]. This is because many of the symptoms that may be attributed to hyperparathyroidism (such as pain, weakness, and pruritus) are nonspecific and are present in patients on dialysis who do not have significant hyperparathyroidism. PTH levels lower than 800 pg/mL are less likely to be the cause of such symptoms.</p><p>Symptoms should be critically evaluated to make sure that other obvious causes are not present. The medical management should be reviewed to make sure treatment is optimized. (See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Treat high parathyroid hormone'</a>.)</p><p>The following signs and symptoms potentially warrant parathyroidectomy in the setting of elevated PTH values. Data supporting parathyroidectomy are provided.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercalcemia and refractory hyperphosphatemia </strong>– Hypercalcemia and refractory hyperphosphatemia are the most common reasons for parathyroidectomy to treat refractory hyperparathyroidism [<a href="#rid23">23</a>]. Other causes of hypercalcemia should be excluded, and the treatment of hyperphosphatemia should be reviewed before the parathyroidectomy to be certain that medical options have been tried. (See  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Patients on dialysis'</a>.)</p><p></p><p class="bulletIndent1">Parathyroidectomy effectively treats hyperparathyroidism-related hypercalcemia and hyperphosphatemia [<a href="#rid24">24-26</a>]. In a study of 1402 patients, the median calcium concentration fell from 9.6 to 7.9 mg/dL, and the serum phosphorus fell from 6.8 to 3.8 mg/dL following parathyroidectomy [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone pain, pruritus, and myopathy </strong>– Bone pain and/or fractures; severe, unexplained muscle weakness; or pruritus are potential indications for parathyroidectomy. These symptoms are nonspecific, however, and, as noted above, commonly observed in patients on dialysis who do not have refractory hyperparathyroidism. Symptoms should not be attributed to hyperparathyroidism (particularly if the PTH is &lt;800 pg/mL) unless other causes have been excluded. (See  <a class="medical medical_review" href="/z/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5158.html" rel="external">"Myopathies of systemic disease"</a>.)</p><p></p><p class="bulletIndent1">Bone pain, in particular, may be due to other forms of renal osteodystrophy, such as adynamic bone disease, which may be worsened by parathyroidectomy. While adynamic bone disease is virtually excluded by PTH &gt;800 pg/mL, lower PTH values (particularly closer to 450 pg/mL) do not conclusively exclude this form of bone disease [<a href="#rid27">27</a>]. Thus, if parathyroidectomy is considered in a patient who has bone pain and PTH &lt;800 pg/mL, a bone biopsy should be performed first. (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>.)</p><p></p><p class="bulletIndent1">Parathyroidectomy effectively treats hyperparathyroidism-related bone pain, pruritus, and myopathy [<a href="#rid24">24-26</a>]. In one study that included 91 end-stage kidney disease (ESKD) patients (80 on dialysis and 11 transplant patients), symptoms of bone pain and weakness were alleviated in 95 percent [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calciphylaxis </strong>– Calciphylaxis (calcific uremic arteriolopathy) is associated with severe hyperparathyroidism and is a potential indication for parathyroidectomy. However, parathyroidectomy has not been conclusively shown to provide a beneficial effect. (See  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)", section on 'Summary and recommendations'</a>.)</p><p></p><p class="bulletIndent1">There have been no systematic or prospective evaluations of the effectiveness of parathyroidectomy due to the sporadic nature of calciphylaxis. Observational reports have suggested improved survival among patients with calciphylaxis who underwent parathyroidectomy. As an example, in a retrospective review of the literature, 38 of 58 patients (66 percent) who underwent parathyroidectomy survived compared with 13 of 37 patients (35 percent) who did not undergo parathyroidectomy [<a href="#rid30">30</a>].</p><p></p><p>In addition to alleviating the signs and symptoms of hyperparathyroidism, parathyroidectomy may also improve survival and other outcomes, although only observational studies are available. (See <a class="local">'Asymptomatic patients'</a> below.)</p><p class="headingAnchor" id="H267003420"><span class="h2">Asymptomatic patients</span><span class="headingEndMark"> — </span>We refer for parathyroidectomy select patients on dialysis who have PTH levels persistently &gt;1000 pg/mL despite optimal medical management, even in the absence of associated clinical symptoms [<a href="#rid31">31</a>]. Among such patients, parathyroidectomy may reduce mortality, cardiovascular risk, and the risk of fracture, although benefits have only been shown in observational studies.</p><p>Optimal medical management is defined as treatment with phosphate binders, active vitamin D analogs, and calcimimetics. (See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Treatment approach'</a>.)</p><p>However, this is a controversial issue, and there is little consensus among experts regarding the indication for parathyroidectomy [<a href="#rid32">32</a>]. </p><p>In particular, there is concern that increased PTH alone is insufficient evidence of high-turnover bone disease. However, in our experience, very high PTH concentrations (such as that which provides indication for parathyroidectomy) correlate better with bone turnover than do those in target range of two to nine times the upper limit of normal.</p><p>Some clinicians use bone-specific alkaline phosphatase in addition to PTH as an indication for parathyroidectomy; concordantly, elevated levels of PTH and alkaline phosphatase have been proposed as a useful indicator of severity. However, in a large bone biopsy study, both PTH and bone-specific alkaline phosphatase were able to predict high-turnover bone disease, and the combination of the two tests added minimal additional predictive value [<a href="#rid33">33</a>].</p><p>The selection of patients for parathyroidectomy must be individualized, depending on age and comorbidities. We generally reserve parathyroidectomy for younger patients (ie, &lt;65 years) who have few comorbidities. Such patients are most likely to tolerate surgery and reap the potential long-term benefits of parathyroidectomy.</p><p>The absence of clinical symptoms may warrant a closer examination for underlying bone disease since symptoms are often subtle and many patients who actually do have bone disease may not describe pain. However, even in patients who do have subtle symptoms that may be attributed to hyperparathyroidism, these symptoms would not provide an indication for parathyroidectomy with PTH &lt;1000 pg/mL.</p><p>Possible benefits of parathyroidectomy include decreased mortality, increased bone density and reduced fracture risk, decreased resistance to erythropoietin, and improved nutrition [<a href="#rid34">34-46</a>]. These are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival </strong>– Outcomes data following parathyroidectomy are entirely from observational studies. A number of studies have suggested that parathyroidectomy is associated with increased survival [<a href="#rid34">34,35,47</a>]. In one study, 150 patients on dialysis who underwent parathyroidectomy at one institution were compared with 1044 matched control patients who did not undergo parathyroidectomy, identified from the United States Renal Data System (USRDS) registry [<a href="#rid35">35</a>]. The mean PTH value among the parathyroidectomy cohort was 1776 pg/mL. At a mean follow-up of 3.6 years, compared with controls, parathyroidectomy was associated with decreased mortality (hazard ratio [HR] 0.68, 95% CI 0.52-0.89).</p><p></p><p class="bulletIndent1">Improved survival may be related to decreased cardiovascular mortality. In a study of 4428 patients who underwent parathyroidectomy and were compared with matched controls who did not undergo parathyroidectomy despite severe hyperparathyroidism, parathyroidectomy was associated with 34 and 41 percent lower risks for all-cause and cardiovascular mortality at one year [<a href="#rid47">47</a>]. This survival benefit was not evident in patients who had persistent secondary hyperparathyroidism postoperatively. In fact, the hazard ratio for mortality was lowest in those with the lowest postoperative PTH levels.</p><p></p><p class="bulletIndent1">However, there is a relatively high mortality immediately following the procedure, and morbidity increases during the first year following parathyroidectomy. Using data obtained from the medical evidence report (which provides diagnostic information on all new ESKD patients in the United States), the United Network for Organ Sharing (UNOS) database, and Medicare claims, one analysis compared adverse events that occurred before and after parathyroidectomy in 4435 selected ESKD patients [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1">Mortality was 2 percent during the immediate hospitalization and in the 30 days following discharge. Twenty-five percent of patients required an intensive care unit (ICU) admission during the immediate hospitalization.</p><p></p><p class="bulletIndent1">Twenty-four percent of patients were rehospitalized in the 30 days following discharge, and 29 percent of these required an ICU admission. One-year morbidity and mortality rates have been reported from analyses of data from the USRDS [<a href="#rid34">34,48</a>].</p><p></p><p class="bulletIndent1">It is not clear whether these results may be generalized to a broader ESKD population, since all included patients were Medicare participants who were undergoing in-center hemodialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone density and fracture risk </strong>– Parathyroidectomy may increase bone density and reduce the risk of fracture. Multiple single-center case series have reported increased bone mineral density after parathyroidectomy [<a href="#rid36">36-38</a>]. One retrospective, case-control study found that parathyroidectomy was associated with reduced risk for hip fracture (0.68, 95% CI 0.54-0.86) and all fractures (0.69, 95% CI 0.57-0.83) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– Some studies have suggested improvements in erythropoietin-resistant anemia [<a href="#rid40">40-42</a>], nutritional status, and humoral and cellular immunity [<a href="#rid43">43,44</a>].</p><p></p><p class="headingAnchor" id="H267003444"><span class="h1">PATIENTS AWAITING TRANSPLANTATION</span><span class="headingEndMark"> — </span>For patients who are actively awaiting transplantation and have refractory hyperparathyroidism, we consult with the transplant center regarding the timing of parathyroidectomy. There is variability among transplant centers in the recommended approach for potential transplant recipients who have refractory hyperparathyroidism.</p><p>Most transplant experts suggest parathyroidectomy for patients with severe refractory hyperparathyroidism and moderate to severe symptoms, particularly if transplantation is not imminent. For patients with refractory hyperparathyroidism who have mild or no symptoms, transplant nephrologists have differing recommendations, although the threshold PTH for parathyroidectomy is typically lower compared with patients who are not awaiting transplantation. (See  <a class="medical medical_review" href="/z/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation", section on 'Prevention'</a>.)</p><p>A rationale for performing parathyroidectomy prior to transplant is that refractory hyperparathyroidism fails to resolve in many patients after transplantation (see  <a class="medical medical_review" href="/z/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation", section on 'Pathophysiology'</a>) [<a href="#rid49">49-51</a>]. Persistent hyperparathyroidism following transplantation may lead to hypercalcemia, hypophosphatemia, and decreased graft function [<a href="#rid52">52-54</a>]. In addition, parathyroidectomy may be safer if performed prior to transplantation. Parathyroidectomy performed after transplantation has been associated with abrupt deterioration of kidney allograft function [<a href="#rid55">55</a>]. </p><p>For potential recipients of deceased-donor kidneys, but not living-donor kidneys, the decision regarding parathyroidectomy may also depend on the anticipated time on the waiting list, which will vary based upon the geographic region. The indications for parathyroidectomy for patients who are expected to have a prolonged wait on the deceased-donor waiting list are likely the same as for patients who are not awaiting transplantation. (See <a class="local">'Symptomatic patients'</a> above and <a class="local">'Asymptomatic patients'</a> above.)</p><p class="headingAnchor" id="H678850655"><span class="h1">KIDNEY TRANSPLANT RECIPIENTS</span><span class="headingEndMark"> — </span>The indications for parathyroidectomy in transplant recipients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation"</a>.)</p><p class="headingAnchor" id="H1561434825"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112930.html" rel="external">"Society guideline links: Chronic kidney disease-mineral and bone disorder"</a>.)</p><p class="headingAnchor" id="H2773660"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of refractory hyperparathyroidism</strong> – We define refractory hyperparathyroidism as persistent and progressive elevations of serum parathyroid hormone (PTH) that cannot be lowered to acceptable levels by medical therapy (including both vitamin D analogs and calcimimetics) without causing significant hyperphosphatemia or hypercalcemia. (See <a class="local">'Definitions and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic patients</strong> – We refer for parathyroidectomy most patients on dialysis who have persistent hyperparathyroidism (PTH levels &gt;800 pg/mL), which is refractory to medical therapies and is accompanied by clearly related signs and symptoms. Parathyroidectomy is effective in mitigating most hyperparathyroidism-associated signs and symptoms. It is important to exclude other potential causes of the signs and symptoms prior to parathyroidectomy. (See <a class="local">'Symptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients</strong> – We perform parathyroidectomy for selected patients on dialysis who have very severe, sustained hyperparathyroidism (PTH levels &gt;1000 pg/mL) that is refractory to medical therapies, even if not accompanied by associated signs and symptoms. The selection of patients must be individualized, depending on age and comorbidities. We generally reserve parathyroidectomy for younger patients (ie, &lt;65 years) and with few comorbidities. Potential but unproven benefits may include improved survival, fracture risk, nutrition, and anemia. (See <a class="local">'Asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients awaiting transplantation</strong> – For patients with refractory hyperparathyroidism who are actively awaiting transplantation, decisions regarding parathyroidectomy should be jointly made with the transplant center. (See <a class="local">'Patients awaiting transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H368504732"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert E Cronin, MD, and Michael Berkoben, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Indridason OS, Heath H 3rd, Khosla S, et al. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int 1996; 50:1663.</a></li><li><a class="nounderline abstract_t">Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328.</a></li><li><a class="nounderline abstract_t">Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436.</a></li><li><a class="nounderline abstract_t">Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6:913.</a></li><li><a class="nounderline abstract_t">Krause MW, Hedinger CE. Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 1985; 16:772.</a></li><li><a class="nounderline abstract_t">van der Plas WY, Noltes ME, van Ginhoven TM, Kruijff S. Secondary and Tertiary Hyperparathyroidism: A Narrative Review. Scand J Surg 2020; 109:271.</a></li><li><a class="nounderline abstract_t">Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77:232.</a></li><li><a class="nounderline abstract_t">Foley RN, Li S, Liu J, et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16:210.</a></li><li><a class="nounderline abstract_t">Li S, Chen YW, Peng Y, et al. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis 2011; 57:602.</a></li><li><a class="nounderline abstract_t">Kim SM, Long J, Montez-Rath ME, et al. Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. Clin J Am Soc Nephrol 2016; 11:1260.</a></li><li><a class="nounderline abstract_t">EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab 2013; 98:4834.</a></li><li><a class="nounderline abstract_t">Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017; 317:156.</a></li><li><a class="nounderline abstract_t">Stephens JM, Fox KM, Desai P, et al. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes. Hemodial Int 2022; 26:243.</a></li><li><a class="nounderline abstract_t">Cunningham J, Block GA, Chertow GM, et al. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep 2019; 4:987.</a></li><li class="breakAll">Moe, Sharon M, Sprague SM. Mineral Bone Disorders in Chronic Kidney Disease. In: The Kidney, 8th, Barry M. Brenner (Ed), Saunders Elsevier, Philadelphia 2008. Vol 2, p.1785.</li><li class="breakAll">Coyne DW, Larson DS, Delmez JA. Bone Disease. In: Handbook of Dialysis, 5th, Daugirdas JT, Blake PG, Ing TS (Eds), Wolters Kluwer, Philadelphia 2015. p.665.</li><li><a class="nounderline abstract_t">Grecomoro G, Camarda L, Martorana U. Simultaneous chronic rupture of quadriceps tendon and contra-lateral patellar tendon in a patient affected by tertiary hyperparatiroidism. J Orthop Traumatol 2008; 9:159.</a></li><li><a class="nounderline abstract_t">Anderson WE 3rd, Habermann ET. Spontaneous bilateral quadriceps tendon rupture in a patient on hemodialysis. Orthop Rev 1988; 17:411.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Singh K, Kleiner M, et al. Nontraumatic bilateral rupture of patellar tendons in a diabetic dialysis patient with secondary hyperparathyroidism. Nephrol Dial Transplant 1997; 12:1988.</a></li><li><a class="nounderline abstract_t">Jones N, Kjellstrand CM. Spontaneous tendon ruptures in patients on chronic dialysis. Am J Kidney Dis 1996; 28:861.</a></li><li><a class="nounderline abstract_t">Gameiro J, Duarte I, Outerelo C, Lopes JA. Uremic lion face syndrome. J Bras Nefrol 2019; 41:304.</a></li><li><a class="nounderline abstract_t">Tang JA, Friedman J, Hwang MS, et al. Parathyroidectomy for tertiary hyperparathyroidism: A systematic review. Am J Otolaryngol 2017; 38:630.</a></li><li><a class="nounderline abstract_t">Punch JD, Thompson NW, Merion RM. Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients. A 25-year single-center experience. Arch Surg 1995; 130:538.</a></li><li><a class="nounderline abstract_t">Tominaga Y, Uchida K, Haba T, et al. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 2001; 38:S168.</a></li><li><a class="nounderline abstract_t">Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44:481.</a></li><li><a class="nounderline abstract_t">Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44:860.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.</a></li><li><a class="nounderline abstract_t">Wetmore JB, Liu J, Do TP, et al. Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. Nephrol Dial Transplant 2016; 31:103.</a></li><li><a class="nounderline abstract_t">Hafner J, Keusch G, Wahl C, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995; 33:954.</a></li><li><a class="nounderline abstract_t">Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis 2011; 58:1022.</a></li><li><a class="nounderline abstract_t">Wetmore JB, Liu J, Dluzniewski PJ, et al. Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis. BMC Surg 2016; 16:77.</a></li><li><a class="nounderline abstract_t">Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67:559.</a></li><li><a class="nounderline abstract_t">Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66:2010.</a></li><li><a class="nounderline abstract_t">Sharma J, Raggi P, Kutner N, et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 2012; 214:400.</a></li><li><a class="nounderline abstract_t">Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:3845.</a></li><li><a class="nounderline abstract_t">Chou FF, Chen JB, Lee CH, et al. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg 2001; 136:1064.</a></li><li><a class="nounderline abstract_t">Yano S, Sugimoto T, Tsukamoto T, et al. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Horm Metab Res 2003; 35:259.</a></li><li><a class="nounderline abstract_t">Rudser KD, de Boer IH, Dooley A, et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18:2401.</a></li><li><a class="nounderline abstract_t">Rault R, Magnone M. The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO J 1996; 42:M901.</a></li><li><a class="nounderline abstract_t">Jemcov TK, Petakov M, Bogdanovic A, et al. Parathyroidectomy and improving anemia. Arch Surg 2008; 143:97.</a></li><li><a class="nounderline abstract_t">Chow TL, Chan TT, Ho YW, Lam SH. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg 2007; 142:644.</a></li><li><a class="nounderline abstract_t">Yasunaga C, Nakamoto M, Matsuo K, et al. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 1999; 178:332.</a></li><li><a class="nounderline abstract_t">Tzanno-Martins C, Futata E, Jorgetti V, Duarte AJ. Restoration of impaired T-cell proliferation after parathyroidectomy in hemodialysis patients. Nephron 2000; 84:224.</a></li><li><a class="nounderline abstract_t">Pizzarelli F, Fabrizi F, Postorino M, et al. Parathyroidectomy and blood pressure in hemodialysis patients. Nephron 1993; 63:384.</a></li><li><a class="nounderline abstract_t">Ifudu O, Matthew JJ, Macey LJ, et al. Parathyroidectomy does not correct hypertension in patients on maintenance hemodialysis. Am J Nephrol 1998; 18:28.</a></li><li><a class="nounderline abstract_t">Komaba H, Taniguchi M, Wada A, et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 88:350.</a></li><li><a class="nounderline abstract_t">Ishani A, Liu J, Wetmore JB, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 2015; 10:90.</a></li><li><a class="nounderline abstract_t">Schmid T, Müller P, Spelsberg F. Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12:2393.</a></li><li><a class="nounderline abstract_t">Ferreira GF, Montenegro FL, Machado DJ, et al. Parathyroidectomy after kidney transplantation: short-and long-term impact on renal function. Clinics (Sao Paulo) 2011; 66:431.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004; 19:1281.</a></li><li><a class="nounderline abstract_t">Messa P, Cafforio C, Alfieri C. Clinical impact of hypercalcemia in kidney transplant. Int J Nephrol 2011; 2011:906832.</a></li><li><a class="nounderline abstract_t">Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5:1934.</a></li><li><a class="nounderline abstract_t">Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007; 21:558.</a></li><li><a class="nounderline abstract_t">Rostaing L, Moreau-Gaudry X, Baron E, et al. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997; 47:248.</a></li></ol></div><div id="topicVersionRevision">Topic 1838 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914034" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995751" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8397225" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454719" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4018775" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pathologic study of parathyroid glands in tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31364494" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Secondary and Tertiary Hyperparathyroidism: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19890272" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563573" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186072" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269300" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121374" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24108314" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097356" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34931443" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31317120" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31317120" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31317120" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384613" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Simultaneous chronic rupture of quadriceps tendon and contra-lateral patellar tendon in a patient affected by tertiary hyperparatiroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3405626" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spontaneous bilateral quadriceps tendon rupture in a patient on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9306357" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nontraumatic bilateral rupture of patellar tendons in a diabetic dialysis patient with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957038" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Spontaneous tendon ruptures in patients on chronic dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30720853" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Uremic lion face syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28735762" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Parathyroidectomy for tertiary hyperparathyroidism: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7748094" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients. A 25-year single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576947" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332221" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8258962" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26292694" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490365" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018457" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : CKD-mineral and bone disorder: core curriculum 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27899108" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321176" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496173" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Survival following parathyroidectomy among United States dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22463880" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improved long-term survival of dialysis patients after near-total parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814456" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529832" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12778370" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634437" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fracture risk after parathyroidectomy among chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8945016" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209161" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Parathyroidectomy and improving anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638802" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10587194" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720892" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Restoration of impaired T-cell proliferation after parathyroidectomy in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459871" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Parathyroidectomy and blood pressure in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9481436" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Parathyroidectomy does not correct hypertension in patients on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786097" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516915" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394329" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21552668" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Parathyroidectomy after kidney transplantation: short-and long-term impact on renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993493" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21760999" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical impact of hypercalcemia in kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996242" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645720" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9128792" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
